Reusing excess staple oligonucleotides for economical production of DNA origami
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Giorgia Isinelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States. Hauptthemen laut MEDLINE: DNA, Oligonucleotides, Nanostructures, Nucleic Acid Conformation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Claudia Adams Barr Program.
Abstract (Originalsprache)
DNA origami has enabled the development of responsive drug-delivery vehicles with precision features that were previously not attainable in bionanotechnology. To reduce the costs of creating therapeutic-scale amounts of DNA origami that need to bear costly modifications with high occupancy, we reused the excess staple oligonucleotides that are left over from the folding process to fold additional origami. We determined that a DNA origami can be successfully folded with up to 80% cost savings by cyclic recovery and reuse of excess staple strands. We found evidence that higher-quality staple strands are preferentially incorporated into origami, consistent with past reports, and therefore are preferentially depleted from the free-strand pool. The folding of DNA origami with staple strands that were reused up to 11 times was indistinguishable by our panel of assays versus a control folded with new strands, so long as the reused oligonucleotides were replenished each cycle with a small excess of fresh strands. We also continued to observe a high degree of cargo loading [e.g. oligo with PS backbone modification (CpG), fluorophores (Cy5 or Cy3), smaller nanostructures (nanocube), etc.] on the origami with each folding cycle. By recovering, reusing, and replenishing excess staple oligonucleotides, it is possible to significantly lessen production costs to create well-formed origami, which is useful to allow more therapeutic designs to be tested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States.
- Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02115, United States.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, United States.
- Department of Drug Science and Pharmacology, University of Catania, Catania 95125, Italy.
ORCID-Profile: William M Shih
Förderung
- NIH HHS
- NCI NIH HHS
- Claudia Adams Barr Program
- Dana–Farber Cancer Institute
- Wyss validation funding
- Wyss Institute for Biologically Inspired Engineering
- NIH
- University of Catania
Zitieren
APA
Isinelli, G., Wintersinger, C. M., Aquilina, M., Lill, P., Young, O. J., Deng, J., Shih, W. M., & Zeng, Y. C. (2025). Reusing excess staple oligonucleotides for economical production of DNA origami. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf527
Vancouver
Isinelli G, Wintersinger CM, Aquilina M, Lill P, Young OJ, Deng J, et al. Reusing excess staple oligonucleotides for economical production of DNA origami. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf527
BibTeX
@article{Isinelli2025,
author = {Isinelli, Giorgia and Wintersinger, Christopher M and Aquilina, Matthew and Lill, Pascal and Young, Olivia J and Deng, Jie and Shih, William M and Zeng, Yang C},
title = {Reusing excess staple oligonucleotides for economical production of DNA origami},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf527}
}
EUVIMED